Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
Analysis of 607 of 1113 records in Mayo Clinic Electronic Health Record database found that COVID-19 patients administered unfractionated heparin but not enoxaparin had higher rates of 28-day mortality (risk ratio: 4.3; 95% CI; 1.8-10.2).
Source:
EClinical Medicine